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Pneumococcal conjugate vaccine – a health priority
Heather J Zar, Shabir A Madhi
Pneumonia is a major cause of childhood mortality and 
morbidity globally, resulting in 2 million deaths a year.1-3 
Pneumonia is the direct cause of approximately 20% of all 
childhood deaths. In addition, for every death directly 
attributable to pneumonia, there are 2 to 3 additional deaths 
due to comorbid conditions such as malnutrition or measles.1 
The overwhelming burden of childhood pneumonia and 
associated deaths is in developing countries, 1-3 in many of 
which the HIV epidemic has increased the incidence, severity 
and complexity of childhood pneumonia.
In South Africa, childhood pneumonia has been a major 
cause of mortality for decades. Despite improvements in access 
to care, greater health equity and economic growth, the under-
5 mortality rate in South Africa has increased to 66 per 1 000, 
representing an increase of 1.3% from 1995 to 1999 and of 1.6% 
from 2000 to 2003.4 This is in contrast to the fourth Millennium 
Development Goal which aims to reduce childhood mortality 
by two-thirds by 2015. In South Africa this would mean a 
reduction in under-5 mortality from 60 per 1 000 in 1995 to 20 
per 1 000 by 2015.5
The burden of pneumococcal 
pneumonia
Bacterial infections are the major preventable cause of 
hospitalisation and death from pneumonia in children in 
developing countries. Among children who died of respiratory 
disease in Zambia, bacterial pneumonia was the most 
commonly identified cause of death in 41% of HIV-infected 
and 50% of HIV-uninfected children. Co-existing other non-
bacterial respiratory pathogens were also frequently identified.6 
Streptococcus pneumoniae is the most important bacterial 
pathogen causing pneumonia in HIV- infected and -uninfected 
children.7-9
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Pneumonia is a major cause of childhood mortality and 
morbidity. Streptococcus pneumoniae is the most important 
bacterial pathogen causing pneumonia in children. The HIV 
epidemic has increased the burden and severity of childhood 
pneumococcal pneumonia and invasive disease fortyfold.
Pneumococcal conjugate vaccine (PCV) is a highly effective 
intervention to reduce invasive pneumococcal disease and 
pneumonia. Studies evaluating a 9-valent PCV in South Africa 
and The Gambia reported a 72 - 77% reduction in vaccine-
serotype-specific invasive disease in vaccinated children. 
As many of the pneumococcal serotypes  associated with 
antibiotic resistance are included in PCV, vaccination has also 
been associated with a reduction in antimicrobial-resistant 
invasive disease. PCV may also reduce childhood mortality, 
especially in places with limited access to health care, as 
shown in Gambian study in which PCV reduced childhood 
mortality by 16%. In addition to the direct effects of PCV, 
there is a substantial reduction in disease burden through 
indirect protection of non-vaccinated populations.
PCV is immunogenic in HIV-infected children and provides 
protection against invasive disease or pneumonia in a 
substantial number of children. Although the efficacy of PCV 
for prevention of invasive disease or pneumonia is lower in 
HIV-infected compared to -uninfected children, the overall 
burden of disease prevented is much greater in HIV-infected 
children because of the higher burden of pneumococcal 
disease in these children. Consequently, vaccine-preventable 
invasive disease is almost 60 times higher in HIV-infected 
compared to -uninfected children, while the reduction in 
pneumonia in HIV-infected children is 15 times greater. 
However, the long-term efficacy of PCV wanes in HIV-
infected children who are not taking antiretroviral therapy, 
and booster doses are probably indicated.
Although there is concern about the potential for 
replacement disease due to non-vaccine serotypes, a 
substantial and sustained reduction in invasive disease has 
occurred overall in populations with widespread childhood 
immunisation. Routine childhood immunisation is now the 
standard of care in most developed countries. However, PCV 
is much less accessible to children in developing countries 
due to cost and availability. Cost-effectiveness analysis 
indicates that use of PCV is potentially highly cost-effective, 
at tiered pricing, even in very low-income countries.
Widespread availability and vaccination with PCV is 
urgently needed for all children under 2 years of age in 
South Africa. In addition, the use of PCV for all HIV-infected 
children under 9 years should be prioritised.
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S. pneumoniae causes between 1 and 4 million episodes of 
pneumonia in Africa each year.10 Bacteraemia occurring with 
pneumonia is a severe manifestation of disease. The incidence 
of pneumococcal bacteraemia or invasive pneumococcal 
disease (IPD) is 9 - 43 times greater in HIV-infected than in 
HIV-uninfected children.11,12 Thus, the incidence of bacteraemic 
pneumococcal pneumonia has increased exponentially as the 
HIV epidemic has escalated in South Africa. For example, the 
incidence of IPD has increased from 200 per 100 000 children 
per year in 1987 (before the onset of the HIV epidemic) to 
380 by 1996 - 1997, and to more than 500 cases per 100 000 
children in 200513 (unpublished data for 2005 – S A Madhi.)  
Importantly, 75% of serious IPD in South African children 
occurs in the 5 - 6% of the childhood population who are 
HIV-infected.11
The minimum burden of pneumococcal pneumonia in South 
African children can be estimated by using pneumococcal 
conjugate vaccine (PCV) as a probe. In a South African trial 
using a 9-valent PCV, the burden of pneumonia prevented 
by vaccine in HIV-infected children (2 573 cases prevented 
per 100 000 child-years) was almost ten times that in HIV-
uninfected (267 cases prevented per 100 000 child-years).14 
Globally, pneumococcal disease is the leading cause of vaccine-
preventable death in children <5 years of age. The World 
Health Organization (WHO) has estimated that, at current 
levels of global coverage for 3 doses of diptheria-tetanus-
pertussis (DTP3) vaccine in the EPI immunisation programme, 
as many as 430 000 deaths could be prevented annually 
by introducing PCV into developing countries. If global 
vaccination coverage for DTP3 increased to 90%, almost  
900 000 childhood deaths could be prevented.15
Childhood pneumonia is frequently caused by mixed 
infections such as bacterial-viral or bacterial-mycobacterial 
pathogens, resulting in more severe illness.9 As evidence of 
this, children who received PCV were less likely to develop 
severe viral-associated pneumonia requiring hospitalisation, 
with a 32% reduction in admissions for viral-associated 
pneumonia in immunised children.16 Moreover, mortality 
rates from pneumonia increase exponentially with increasing 
numbers of pathogens. Children with polymicrobial 
pneumonia have a tenfold greater risk of dying than children 
in whom only a single organism is identified.9
Prevention of pneumococcal 
pneumonia in children using conjugate 
vaccine
The development of PCV has been a major advance 
in preventing pneumoccocal pneumonia. Unlike the 
polysaccharide pneumococcal vaccines, which are poorly 
immunogenic in children under 5 years of age, PCV is 
immunogenic, safe and effective in children immunised 
from 6 weeks of age onward. Globally, about 20 serotypes 
are associated with more than 80% of IPD, with the 13 most 
common serotypes causing at least 70 - 75% of invasive disease 
in children.15 The only commercially available PCV includes 7 
serotypes (PCV7) which cause almost 70% of all IPD in South 
African children.17 Changing from the 7-valent to a 10-valent 
vaccine would increase the proportion of serotypes covered 
from 67% to 81% in African, and to 85% in South African, 
children.15,17 Further improvements in serotype coverage 
may occur with added serotypes being included in future 
formulations.
Efficacy of pneumococcal conjugate 
vaccine
Pneumococcal conjugate vaccine is highly effective against 
serotype-specific IPD. An evaluation of PCV7 in  the USA 
showed a 94% reduction in IPD from vaccine strains.18 
Evaluation of a 9-valent PCV in South Africa and The Gambia 
demonstrated a 72 - 77% reduction in vaccines-serotype (VT)-
specific IPD among vaccinated children (Table I).19,20 The 
efficacy against IPD regardless of pneumococcal serotype was 
45% in Gambia.20 Although the efficacy against VT-IPD was 
lower in HIV-infected (65%) than HIV-uninfected children 
(83%) in South Africa, the absolute burden of IPD prevented by 
vaccination was 18 times greater in HIV-infected children (570 
v. 32 per 100 000 children vaccinated, respectively).19
Further evidence of the efficacy of PCV comes from 
the impact on IPD in high-risk paediatric populations. In 
Alaskan children, IPD rates have fallen dramatically since 
the introduction of PCV7 in 2001.21 In Australian Aboriginal 
children under 2 years of age, 3 doses of PCV7 plus a dose of 
23-valent vaccine at 18 months reduced VT-IPD  from 118 to 
43/100 000/year, even though the coverage was only about 
54%.22 The rate of non-vaccine serotype IPD remained constant 
at 31/100 000/year.
The incidence of radiologically confirmed pneumonia is 
also reduced by vaccination, varying from 13% to 37% (Table 
II).19,20,23 Based on WHO-defined radiological pneumonia, the 
Table I. Efficacy (midpoint efficacy estimate, 95% 
confidence interval) of pneumococcal conjugate vaccine 
for invasive disease in children
Study                 Vaccine serotypes All serotypes
USA   (7-valent)   94% (80, 98)  89% (75, 95)
Native American (7-valent) 83% (23, 96%) 46% (–6, 73)
South Africa (9-valent)*
   HIV-infected  65% (24, 86) 53% (21, 73)
   HIV-uninfected  83% (39, 97) 42% (–28, 75)
South Africa (9-valent)†
HIV-infected  39% (–8, 65) 46% (19, 64)
HIV-uninfected  78% (34, 93) 35% (–61, 68) 
Gambia (9-valent)  92% (44, 99) 45% (19, 63)
*Surveillance until 2.5 years of age.
†Extended surveillance until 6 years of age in the absence of any booster dose of 
pneumococcal vaccine.
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adjusted efficacy for prevention of a first episode of pneumonia 
was 25% with PCV7 for intent-to-treat in the USA.24 However, 
the sensitivity of chest radiographs in detecting the burden 
of pneumococcal pneumonia (as defined by WHO criteria) 
may underestimate the burden of disease by as much as 63%. 
The true burden of pneumococcal pneumonia prevented by 
vaccination may therefore be much greater than that detected 
by chest radiographs. As evidence of this, a North American 
study reported a 61% reduction in all-cause pneumonia 
admissions in children <2 years associated with routine use of 
PCV7 compared with the pre-vaccination era.25
As many of the pneumococcal serotypes associated with 
antibiotic resistance are included in PCV7, vaccination 
with PCV has also been associated with a reduction in 
antimicrobial-resistant IPD. After the introduction of PCV7, 
the USA experienced an 80% decline in IPD caused by 
penicillin-resistant strains in young children.26 In the South 
African PCV9 study, a reduction in IPD from penicillin and 
trimethoprim-sulfamethoxazole resistant strains of 67% and 
56% respectively was found in immunised children.19 Given the 
increasing prevalence of drug-resistant pneumococci, a vaccine 
that reduces IPD and carriage of potentially drug-resistant 
serotypes is of major public health value.
The impact of PCV on childhood mortality depends on the 
context and availability of health care. PCV9 reduced all-cause 
childhood mortality by 16% in Gambia, in which children 
from an impoverished rural population with limited access to 
health care were enrolled.20 In contrast, in the South African 
study in the urban setting of Soweto, where children have 
free access to primary and hospital health care, no effect on 
childhood mortality was evident.27 Therefore the benefit of 
vaccination against mortality will be greatest among vulnerable 
populations with limited access to health care.
In addition to the direct effects of PCV, there is a substantial 
reduction in disease burden through indirect protection of 
non-vaccinated populations. Children (who are the primary 
means of transmission of pneumococci) are protected against 
colonisation with vaccine serotypes after PCV immunisation.28 
Consequently, reduced colonisation by vaccine serotypes 
in vaccinated children interrupts the transmission of these 
serotypes and reduces the risk of other susceptible individuals 
in the community becoming colonised. As evidence of this 
indirect protection, the rate of VT-IPD in the USA has fallen 
across age groups. The reduction in IPD has been most marked 
in children <5 years of age (who are the target group for 
immunisation) as well as in the age groups of 40 - 65 years and 
>65 years (who are not immunised, but have reduced rates 
of disease via the indirect benefit of reduced transmission).29 
Consequently in the USA, universal immunisation of children 
with PCV7 has been estimated to directly reduce the number 
of cases of IPD by approximately 9 000 among vaccinated 
children, while indirect protection resulted in a further 20 000 
cases of IPD being prevented per year.29
Efficacy in HIV-infected children
PCV is immunogenic in HIV-infected children. HIV-infected 
infants on highly active antiretroviral therapy (HAART) have 
similar quantitative antibody responses to PCV, compared with 
HIV-uninfected children.30 However, HIV-infected children 
not on HAART have lower quantitative antibody responses 
to PCV9 and impaired antibody functionality against some 
serotypes, compared with HIV-uninfected children.31
PCV provides protection against IPD and pneumonia in a 
substantial number of HIV-infected children.12,14,19 In South 
Africa, the serotypes included in PCV9 were associated with 
83 - 91% of invasive isolates among HIV-infected children.12 
The efficacy of PCV9 against pneumonia varies, depending 
on the criteria used for defining ‘pneumonia’. For example, 
the median reduction in radiologically confirmed pneumonia 
in HIV-infected children was 13% (95% confidence interval 
–7 to +28), in clinical pneumonia was 15% (6 - 24), and in 
bacteraemic pneumonia was 65% (24 - 86).14 However, the 
vaccine-attributable rate reduction was much greater for 
clinical pneumonia than bacteraemic disease (2 573 cases 
prevented per 100 000 child-years compared with 483 episodes 
of bacteraemic pneumococcal pneumonia prevented per  
100 000 child-years), because the sensitivity of blood cultures in 
diagnosing pneumococcal pneumonia is only 3 - 20%.14
Although the efficacy of  PCV9 for prevention of IPD 
and pneumonia was lower in HIV-infected compared with 
-uninfected children (Tables I and II), the overall burden of 
disease that is prevented is much greater, mainly because of 
the higher underlying burden of pneumococcal disease in 
HIV-infected children.14 Consequently, the overall vaccine-
preventable disease of IPD was almost 60 times higher in 
HIV-infected compared with -uninfected children, while the 
reduction in pneumonia in HIV-infected children was 15 times 
greater at 6 years of follow-up.
The long-term efficacy of PCV wanes in HIV-infected 
children. In the context of limited access to HAART, vaccine 
efficacy against IPD declined in HIV-infected children from 
65% (2.5 years post-vaccination) to 39% by 6 years of age in 
the absence of a booster dose (Table I). In contrast, efficacy was 
maintained in HIV-uninfected subjects.27 However, at 6 years’ 
follow-up, the vaccine-attributable rate reduction in IPD was 
still 59 times greater in HIV-infected children compared with 
HIV-uninfected children (2 250 v. 38 cases prevented per  
Table II. Efficacy (midpoint efficacy estimate, 95% 
confidence interval) of pneumococcal conjugate vaccine 
for pneumonia in children
Study      Radiological Clinical pneumonia
USA (7-valent)     18% (5, 29)       6% (–1.5, 11)
South Africa (9-valent)
   HIV-infected     13% (–7, 28)         15% (6, 24)
   HIV-uninfected     20% (3, 35)         7% (–1, 14)
Gambia (9-valent)     37% (25, 48)            6% (1,11)
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100 000 child-years). The need and benefit of intermittent 
booster doses of PCV requires further evaluation in HIV-
infected children.
The potential indirect benefit of PCV to HIV-infected 
adults through immunisation of children should also not 
be underestimated. Pneumococcal disease, especially that 
caused by serotypes included in PCV7,32 is a major cause of 
mortality and morbidity in HIV-infected adults and in the 
elderly. The potential benefit of childhood immunisation on the 
development of herd immunity in populations with a high HIV 
prevalence needs further study.
Cost efficacy 
A cost-efficacy analysis of 3 vaccine doses in infants, done in 72 
countries eligible for support from Global Alliance for Vaccines 
and Immunization (GAVI), found that vaccines could prevent 
262 000 deaths per year (7% of children aged 3 - 29 months in 
the countries studied).33 This was estimated to save 8.34 million 
disability-adjusted life-years (DALYs) yearly. At $5 per dose, 
vaccination would cost $838 million (a cost of $100 per DALY 
averted) and is highly cost-effective.33 However, South Africa 
does not qualify for GAVI funding and PCV is not included in 
the EPI programme because of cost-constraints related to its 
market price (approximately $50 per dose). A vaccine that will 
especially benefit immunocompromised children, or children 
with poor access to health care facilities, therefore remains 
inaccessible to the children who are most susceptible to 
developing severe disease in this country.
Replacement disease
Replacement with serotypes that are not contained in a vaccine 
is a concern for development of disease and nasopharyngeal 
carriage. However, most serious illness is caused by a relatively 
small number of serotypes.29 Universal immunisation of infants 
with PCV7 reduces the carriage of vaccine strains, which is 
offset by an increase in carriage of non-vaccine pneumococci.28 
Data suggest an increasing emergence of pneumococcal disease 
from non-vaccine serotypes in immunised children.21,34,35 
Although this has predominantly been due to a single serotype 
19A (an important cause of IPD before the introduction 
of PCV in the USA), the absolute magnitude of increased 
disease in the USA because of non-vaccine serotypes has 
been minimal, relative to the burden of disease prevented by 
vaccination.29 Conversely, the burden of non-vaccine serotype 
disease has increased 3 years after the introduction of PCV 
in Alaskan infants, attenuating the reduction in the burden 
of IPD by PCV. However, the overall incidence of IPD is still 
significantly lower compared with the incidence of IPD before 
the introduction of PCV.21 While replacement disease due to 
non-vaccine serotypes may be dealt with by broadening the 
number of serotypes included in PCV, continued monitoring 
of the effect of PCV on the epidemiology of IPD is necessary, 
especially in low-income or emerging-economy countries 
in which a broader range of serotypes has been associated 
with IPD even in the pre-PCV era. Despite the potential for 
replacement disease, a substantial and sustained reduction 
in IPD has occurred overall in populations with widespread 
childhood immunisation.
Recommendations
The use of PCV should be complementary to other 
pneumonia-control measures, including case management 
and the reduction of exposure to known risk factors such 
as malnutrition, biomass fuel exposure, tobacco smoke and 
HIV infection. WHO recommends that the inclusion of 
PCV7 vaccine should be a priority in national immunisation 
programmes, particularly in countries where mortality among 
children under 5 years is more than 50 per 1 000 live births or 
where more than 50 000 children die annually.15 Furthermore, 
WHO recommends that countries with a high prevalence of 
HIV prioritise the introduction of PCV7.15
Widespread availability and vaccination is urgently needed 
for ALL children under 2 years of age in South Africa. The 
introduction of PCV for all HIV-infected children less than 
9 years of age (the upper age limit for which the vaccine is 
approved) should be prioritised. Children living in poorly 
resourced areas or where access to health care is limited, 
stand to benefit the most in terms of potential reduction in 
pneumococcal-associated morbidity and mortality.
The recommended schedule for vaccination in infants is 3 
doses of PCV given intramuscularly at least 4 weeks apart, 
beginning at 6 weeks of age concurrently with the other routine 
childhood vaccines, followed by a booster dose of PCV at 15 - 
18 months of age, which may be especially important in HIV-
infected children (Table III). Children immunised between 12 
and 24 months of age should receive at least 2 doses 1 month 
apart; and children aged 2 - 9 years of age require a single dose 
of PCV (Table III). Additional booster doses may be necessary 
Table III. Recommended immunisation schedule for 
pneumococcal conjugate vaccine (PCV) in HIV-infected 
and uninfected children
Age at initial   
immunisation       Initial doses           Booster dose
<1 year        6 weeks           15 - 18 months
        10 weeks
        14 weeks
1 - 2 years       2 doses,            Nil* 
        1 month apart
2 - 9 years       1 dose           Nil*
*The need for intermittent booster doses of PCV needs to be evaluated further in HIV-
infected children, especially in the absence of antiretroviral therapy.
All doses are given as 0.5 ml intramuscularly.
PCV should be given concurrently with other childhood immunisations.
Pneumococcal polysaccharide vaccine may benefit children >2 years at high risk of 
invasive disease (e.g. post splenectomy, sickle cell disease, etc.) and should be given 
at least 1 month after completion of the primary series of PCV.
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in HIV-infected children in whom immunity wanes and loss of 
protection against invasive disease in the absence of a booster 
dose of PCV occurs.27
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